Aks

Enspectra Health's Initiative to Advance Predictive Algorithms for Skin Precancers Awarded $2M Grant from the NIH.

Retrieved on: 
Wednesday, July 19, 2023
Database, Aks, SCC, Biopsy, SBIR, Deep learning, Association of British HealthTech Industries, Skin cancer, Pathology, Skin, Research, Bangladesh Technical Education Board, Small Business Innovation Research, National Cancer Institute, Conditional sentence, Direct, Patient, Carcinoma, Algorithm, Melanoma, NCI, Pharmaceutical industry, Medical imaging

MOUNTAIN VIEW, Calif., July 19, 2023 /PRNewswire/ -- Enspectra Health, a healthtech company pioneering the virtual biopsy, has been awarded $2M in grant funding from the National Cancer Institute (NCI), part of the National Institutes of Health, through the Small Business Innovation Research (SBIR) Program. The funding will support research for developing deep learning algorithms to predict which precancerous lesions, Actinic Keratosis (AK), are likely to progress to squamous cell carcinoma (SCC), a form of non-melanoma skin cancer. AKs affect more than 58 million Americans1 and can progress to SCC, which kills more Americans than melanoma each year.2 The annual cost of treating non-melanoma skin cancers in the U.S. is estimated to be $4.8 billion.

Key Points: 
  • Unlike slide based scanners that require biopsies for digitization, Enspectra's technology digitizes pathology instantaneously and directly from a subject's skin in vivo.
  • With the NCI grant, Enspectra will build a large database of digital histopathology on patients with AKs before topical therapy is applied.
  • "We are thrilled to have been awarded a Direct-to-Phase II SBIR grant from the NCI to support the development of predictive algorithms for skin precancers," said Gabriel Sanchez, Ph.D., CEO and co-founder of Enspectra Health.
  • "This grant will accelerate our vision to noninvasively detect and monitor skin conditions earlier to advance care for the millions of patients with skin conditions."

New Survey Finds Millennials and Gen Xers Not Following Safe Sun Habits, Increasing Risk of Nonmelanoma Skin Cancer

Retrieved on: 
Wednesday, April 5, 2023
Genetics, Fitness & Nutrition, Marketing, Millennials, Communications, Other Health, Consumer, Health, Generation X, Oncology, DTC, Aks, Carcinoma, DNA, SCC, Gen, Education, Bed, Public opinion, Opinion, ESOMAR, Skin cancer, NMSC, Market Research Society, Woman, New York University, OnePoll, Risk, Multimedia, Tanning, American Association for Public Opinion Research, Skin, Conditional sentence, Dermatology, NYU Langone Health, European Society of Gynaecological Oncology, Research, AAPOR, BCC, News, Cosmetics, Platinum, Leather, MD

Today, the Company launched its Sun Regrets campaign to educate Americans on their skin health as it relates to the risk of skin cancer, the risk factors of nonmelanoma skin cancer and the importance of preventative measures to reduce ultraviolet (UV) damage.

Key Points: 
  • Today, the Company launched its Sun Regrets campaign to educate Americans on their skin health as it relates to the risk of skin cancer, the risk factors of nonmelanoma skin cancer and the importance of preventative measures to reduce ultraviolet (UV) damage.
  • Twenty-nine percent were unlikely to get a skin cancer screening if they didn’t see notable changes in their skin.
  • “As nonmelanoma skin cancer is one of the most common types of skin cancer, it is imperative that we build awareness of what skin cancers look like and how to prevent them.
  • The Sun Regrets campaign is an important resource tool to boost Americans’ knowledge of these common forms of skin cancer.”

Biofrontera Inc.’s Marketing Campaign and Website for Ameluz Won 2022 PM360 Trailblazer Awards

Retrieved on: 
Monday, September 26, 2022
Online, BF, Skin, COVID-19, Silver, Publication, Trailblazer, PDT, Creativity, Company, Premier's Multicultural Communications Awards, Achievement, Industry, Gold, Aks, Patient, Decision-making, CEO, Acosta Sales & Marketing, Nasdaq, Leadership, Private Securities Litigation Reform Act, Impetigo, BFRI, Associate, GLOBE, Overalls, Marketing, SEC, Awareness, Shark, Communication, AK, PR, Pharmaceutical industry, Public relations, Aminolevulinic acid, Dermatology

These awards were announced at the 14th Annual Trailblazer Awards held September 22, 2022 in New York, where they also recognized the previously announced Trailblazer Brand Champion in Dermatology, Leslie Hopkins, Associate Director of Marketing at Biofrontera Inc.

Key Points: 
  • These awards were announced at the 14th Annual Trailblazer Awards held September 22, 2022 in New York, where they also recognized the previously announced Trailblazer Brand Champion in Dermatology, Leslie Hopkins, Associate Director of Marketing at Biofrontera Inc.
  • Biofronteras Ameluz marketing campaign, developed in collaboration with the healthcare-focused branding agency Elevate Healthcare Marketing, was a creative call to action emphasizing the threat of actinic keratoses (AK).
  • The launch of the Ameluz website was a strategic step in a broader initiative to enhance medical support and build brand awareness.
  • Since 2009, the PM360 Trailblazer Awards have recognized outstanding achievement and innovation in healthcare marketing.

Biofrontera, Inc. Recognized for Rapid Sales Growth, Innovative Therapies and Marketing Excellence

Retrieved on: 
Thursday, June 9, 2022
Cryotherapy, Impetigo, BF, Hearing, Company, BFRI, Aks, Marketing, Skin cancer, Squamous cell carcinoma, Awareness, Premier's Multicultural Communications Awards, Patient satisfaction, Nasdaq, Methyl aminolevulinate, Dermatology, Scalp, FDA, GLOBE, Patient, Publication, Private Securities Litigation Reform Act, Shark, Face, Skin Cancer Foundation, COVID-19, PDT, Skin, SEC, Industry, AK, Communication, Pharmaceutical industry

WOBURN, Mass, June 09, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company has been recognized for its contributions to the life sciences industry and for its newest Ameluz® marketing campaign.

Key Points: 
  • Biofrontera was named by CIOCoverage Magazine as one of the 10 fastest-growing life sciences companies to watch in 20221.
  • This campaign, which was developed in collaboration with the healthcare-focused branding agency Elevate Healthcare Marketing, aims to create awareness of the danger associated with visible and invisible AKs.
  • CIOCoverage Magazine recognized Biofrontera for exhibiting excellence in transforming life sciences business, and we aim to keep delivering that excellence throughout 2022 and beyond.
  • AKs typically appear on sun-exposed areas such as the face, bald scalp, arms or the back of the hands.

XENDEE Appoints Akshaya Gulhati as Chief Product Officer

Retrieved on: 
Wednesday, April 20, 2022
Environment, Technology, Finance, Other Energy, Utilities, Professional Services, Software, Alternative Energy, Energy, Other Professional Services, Zero, CEO, Government, Carbon, EV, Lists of stars, Critical, Partner, Boston Consulting Group, Entrepreneurship, Goal, Hydrogen, Company, Solution, Strategy&, Cabinet Secretary for Net Zero, Energy and Transport, Booz, Boston, Multimedia, Aks, ICF International, Management, Renewable energy

XENDEE Corporation , a leader in microgrid decision support and operation software, today announced that it has appointed Akshaya (Aks) Gulhati as Chief Product Officer.

Key Points: 
  • XENDEE Corporation , a leader in microgrid decision support and operation software, today announced that it has appointed Akshaya (Aks) Gulhati as Chief Product Officer.
  • View the full release here: https://www.businesswire.com/news/home/20220420005213/en/
    Former Boston Consulting Group Partner and experienced energy industry advisor, Akshaya (Aks) Gulhati will lead XENDEEs product and service development as Chief Product Officer.
  • Prior to joining XENDEE, Aks worked as a Partner at the Boston Consulting Group.
  • Were thrilled to bring Aks on board as XENDEEs Chief Product Officer and leverage his skills with product strategy, innovation, and digital transformation to help our clients achieve their Scope 1 and 2 emissions goals confidently and reliably.

Almirall U.S. Supports The Skin Cancer Foundation's Mobile Skin Cancer Screening Program

Retrieved on: 
Monday, November 8, 2021
Aks, GM, Cancer, Squamous cell carcinoma, Skin cancer, Science, Mask, Melanoma, Skin Cancer Foundation, Disease, Skin, Mark (given name), COVID, COVID-19, Research, Program, Foundation, Incidence, SCC, Clothing, Almirall, Patient, Risk, City, Medical imaging

MALVERN, Pa., Nov. 8, 2021 /PRNewswire/ -- Almirall U.S. is a proud supporter of The Skin Cancer Foundation's mobile skin cancer screening program, Destination Healthy Skin. The Destination Healthy Skin RV travels to cities across the U.S., where local volunteer dermatologists provide free full-body skin cancer screenings in private exam rooms aboard the RV.

Key Points: 
  • - The Foundation's Destination Healthy SkinRV visits communities around the U.S. toraiseskin cancerawareness
    MALVERN, Pa., Nov. 8, 2021 /PRNewswire/ --Almirall U.S.is a proud supporter of The Skin Cancer Foundation's mobile skin cancer screening program, Destination Healthy Skin.
  • Skin cancer isthe most common form of cancer in the United States,and incidence continues to rise.It's estimated that one in five Americans will develop skin cancer by the age of 70.
  • Dermatologists participating in the Destination Healthy Skin program screen patients for suspected melanomas, nonmelanoma skin cancers and skin precancers, including actinic keratoses.
  • Almirall is proud to support the program and help make skin cancer screenings more accessible."

Akston Biosciences Announces Commercial Supply Agreement of Seppic’s Adjuvant to Formulate Akston Shelf-Stable COVID-19 Vaccine at Global Scale

Retrieved on: 
Wednesday, July 21, 2021
Research, Infectious diseases, Chemicals, Plastics, Clinical trials, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, Other Science, Vaccination, Vaccine, Virology, Subunit vaccine, University Medical Center Groningen, Subunit, Aks, Medicine, Health care, Health

The two companies began collaborating for the development of AKS-452 in the summer of 2020.

Key Points: 
  • The two companies began collaborating for the development of AKS-452 in the summer of 2020.
  • AKS-452 is a protein subunit vaccine that is in Phase II testing at the University Medical Center Groningen (UMCG), one of the largest hospitals in the Netherlands.
  • We are excited to work together to combine the great potential of Akstons AKS-452 with Seppics deep experience in vaccine adjuvants.
  • We are confident about the potential for AKS-452 to transform the global COVID-19 landscape for those most at risk, said Todd Zion, Ph.D., President & CEO of Akston Biosciences.

K8ssandra Now Runs on Any Kubernetes

Retrieved on: 
Tuesday, May 4, 2021
Security, Technology, Other Technology, Software, Networks, Internet, Cloud computing, Cloud infrastructure, Computing, IT infrastructure, Kubernetes, GKE, Aks, Cloud Native Computing Foundation, Mirantis

b'DataStax today announced that K8ssandra , an open-source distribution of Apache Cassandra\xe2\x84\xa2 on Kubernetes, is available on any Kubernetes environment including distro-specific integrations for Amazon Elastic Kubernetes Service (Amazon EKS), Google Kubernetes Engine (GKE), and Azure Kubernetes Service (AKS).\n"Apache Cassandra is a highly scalable, fast and reliable database and running it on Kubernetes removes many of the operation hurdles around installation, customization and maintenance.

Key Points: 
  • b'DataStax today announced that K8ssandra , an open-source distribution of Apache Cassandra\xe2\x84\xa2 on Kubernetes, is available on any Kubernetes environment including distro-specific integrations for Amazon Elastic Kubernetes Service (Amazon EKS), Google Kubernetes Engine (GKE), and Azure Kubernetes Service (AKS).\n"Apache Cassandra is a highly scalable, fast and reliable database and running it on Kubernetes removes many of the operation hurdles around installation, customization and maintenance.
  • Cloudleaf, Inc., a leader in next generation digital supply chain solutions, has been running Cassandra at scale on Kubernetes as a stateful set for several years now as part of its digital visibility platform.
  • With the huge adoption for Cassandra users on Kubernetes, projects like K8ssandra will be a huge boost for the Cassandra community, giving it a complete ecosystem of capabilities such as automated repairs, backups and monitoring.
  • @Amazon Elastic Kubernetes Service, @Google Kubernetes Engine, & @Azure Kubernetes Service.

Spectro Cloud Extends Cluster Management for Existing Kubernetes Deployments

Retrieved on: 
Monday, March 1, 2021
Cloud computing, Cloud infrastructure, Computing, IT infrastructure, Kubernetes, GKE, Aks, Bluemix, Mirantis

SANTA CLARA, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Spectro Cloud, an enterprise cloud-native infrastructure company, today announced support for existing Kubernetes environments, including clusters on public cloud services such as Amazon EKS, Azure AKS and Google GKE, has been added to the Spectro Cloud Kubernetes management platform.

Key Points: 
  • SANTA CLARA, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Spectro Cloud, an enterprise cloud-native infrastructure company, today announced support for existing Kubernetes environments, including clusters on public cloud services such as Amazon EKS, Azure AKS and Google GKE, has been added to the Spectro Cloud Kubernetes management platform.
  • By supporting brownfield environments, Spectro Cloud enables enterprises to get the benefits of consistent cloud management across clustersin the cloud, on site or any combinationwithout having to completely rebuild their existing clusters.
  • Spectro Cloud adds cluster management capabilities to existing clustersincluding Kubernetes-as-a-Service environments such as Amazon EKS, Azure AKS and Google GKEby layering cluster profiles on top of underlying services.
  • Organizations can easily try out Spectro Cloud with existing Kubernetes clusters today by signing up for a free trial and exploring how Spectro Cloud makes cluster management at scale simpler, faster and more consistent.

Cleveland-Cliffs and AK Steel Receive Favorable Recommendations from ISS and Glass Lewis for Votes to Complete Merger

Retrieved on: 
Tuesday, February 25, 2020
Other Natural Resources, Mining, Minerals, Manufacturing, Natural Resources, Other Manufacturing, Steel, Corporate finance, AK Steel Holding, Ashland, Kentucky, Itochu, Zanesville, Ohio, Cleveland-Cliffs Inc., Companies, Aks, Mergers and acquisitions, Glass Lewis, Economy, Business, Cleveland-Cliffs, AK Steel

Cleveland-Cliffs Inc. (NYSE: CLF) (Cliffs or Cleveland-Cliffs) and AK Steel Holding Corporation (NYSE: AKS) (AK Steel) today announced that they have received recommendations from both Glass, Lewis & Co., LLC (Glass Lewis) and Institutional Shareholder Services, Inc. (ISS) to vote in favor of their proposed merger transaction.

Key Points: 
  • Cleveland-Cliffs Inc. (NYSE: CLF) (Cliffs or Cleveland-Cliffs) and AK Steel Holding Corporation (NYSE: AKS) (AK Steel) today announced that they have received recommendations from both Glass, Lewis & Co., LLC (Glass Lewis) and Institutional Shareholder Services, Inc. (ISS) to vote in favor of their proposed merger transaction.
  • Under the pending transaction, Cliffs would acquire all of AK Steels outstanding shares pursuant to the Agreement and Plan of Merger (the Merger Agreement) entered into by Cliffs and AK Steel providing for the merger of a subsidiary of Cliffs with and into AK Steel, with AK Steel surviving as a wholly owned subsidiary of Cliffs (the Merger).
  • Cliffs and AK Steel urge all shareholders to vote in favor of the proposed Merger as promptly as possible.
  • On February 4, 2020, AK Steel also filed with the SEC its definitive joint proxy statement/prospectus in connection with the proposed Merger.